Form 4: Ginkgo Bioworks CFO Mark Dmytruk Reports Stock Transactions

Mark Dmytruk, CFO of Ginkgo Bioworks Holdings, Inc., reports transactions involving Class A and Class B Common Stock, including acquisitions, disposals, and conversions.

Summary

• On March 1, 2024, Mark Dmytruk, the CFO of Ginkgo Bioworks Holdings, Inc., engaged in multiple transactions involving the company's stock.
• These transactions included the acquisition of Class A Common Stock through the vesting of restricted stock units (RSUs).
• Dmytruk also converted shares of Class B Common Stock to Class A Common Stock.
• On March 4, 2024, Dmytruk disposed of 38,826 shares of Class A Common Stock at a price of $1.256 per share.
• These sales were to cover tax withholding obligations related to the vesting of restricted stock and/or restricted stock units.
• Following these transactions, Dmytruk beneficially owns 808,125 shares of Class A Common Stock and 630,319 shares of Class B Common Stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The transactions reported are typical for executives who receive stock-based compensation.
• Similar filings can be observed for executives at companies like Amyris, Zymergen (now Ginkgo Bioworks), and other synthetic biology firms.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a key executive.
• The 'sell to cover' transactions are part of the company's equity incentive plans, impacting employees receiving stock-based compensation.

Key Dates